Notably, cyclin-dependent kinase 4/6 (CDK4/6, cell cycle-related genes) inhibitors have shown significant activity against several cancers and some (namely palbociclib, ribociclib and abemaciclib) are approved for treatment of patients with advanced breast cancer (18). This evidence concerns the gene CDK4 and breast cancer.